<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://eudravigilance.ema.europa.eu/dtd/icsr21xml.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>864720_123</messagenumb>
		<messagesenderidentifier>AMGENSAFETY</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152046</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>DE-AMGEN-DEUCT2013005137</safetyreportid>
		<primarysourcecountry>DE</primarysourcecountry>
		<occurcountry>DE</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130122</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130122</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>DE-AMGEN-DEUCT2013005137</companynumb>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>DE</reportercountry>
			<qualification>1</qualification>
			<studyname>Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcino</studyname>
			<sponsorstudynumb>20080683</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>AMGENSAFETY</senderorganization>
			<senderdepartment>Amgen Global Safety</senderdepartment>
			<sendergivename>Paul</sendergivename>
			<senderfamilyname>Eisenberg</senderfamilyname>
			<senderstreetaddress>One Amgen Center Drive</senderstreetaddress>
			<sendercity>Thousand Oaks</sendercity>
			<senderstate>California</senderstate>
			<senderpostcode>91320</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>8054471000</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>8054994495</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>dsstriage@amgen.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivergivename>Bill</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receivercountrycode>US</receivercountrycode>
			<receiveremailaddress>wtaylor@oc.fda.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bile duct cancer</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Cholangitis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Cholangitis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Cholangitis</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20130121</reactionstartdate>
				<reactionfirsttime>60</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>11</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>panitumumab</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationnumb>125-147</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Amgen</drugauthorizationholder>
				<drugstructuredosagenumb>9</drugstructuredosagenumb>
				<drugstructuredosageunit>007</drugstructuredosageunit>
				<drugdosagetext>9 mg/kg, UNK</drugdosagetext>
				<drugdosageform>Solution for injection</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bile duct cancer</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121122</drugstartdate>
				<drugstartperiod>60</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>11</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20130110</drugenddate>
				<drugtreatmentduration>50</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>panitumumab</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Cholangitis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Cholangitis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>GEMCITABINE</medicinalproduct>
				<drugstructuredosagenumb>1000</drugstructuredosagenumb>
				<drugstructuredosageunit>009</drugstructuredosageunit>
				<drugdosagetext>1000 mg/m2, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bile duct cancer</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121122</drugstartdate>
				<drugstartperiod>60</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>4</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20130117</drugenddate>
				<drugtreatmentduration>57</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>GEMCITABINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CISPLATIN</medicinalproduct>
				<drugstructuredosagenumb>25</drugstructuredosagenumb>
				<drugstructuredosageunit>009</drugstructuredosageunit>
				<drugdosagetext>25 mg/m2, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bile duct cancer</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20121122</drugstartdate>
				<drugstartperiod>60</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>4</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20130117</drugenddate>
				<drugtreatmentduration>57</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>CISPLATIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>The following event was received from a Non-Amgen Sponsored Trial (Investigator Sponsored Study).

This female subject was participating in a randomized clinical phase II study of panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas and developed cholangitis. 

The subjects medical history included cholangiocarcinoma. No previous treatment for the condition under study and no concomitant medications were reported. 

The subject received the first dose of open label investigational product panitumumab in combination with gemcitabine and cisplatin on 22/Nov/2012. Approximately two months later, on 21/Jan/2013, the subject developed cholangitis which required hospitalization. No further details were reported. The subject had not received any therapy and the event remained ongoing at the time of the report. The subjects last dose of investigational product prior to the event was on 10/Jan/2013. The last dose of gemcitabine and cisplatin prior to the event was on 17/Jan/2013. Action taken with investigational product was not provided at the time of the report. 

The investigator reported that there was a reasonable possibility that the event of cholangitis was related to investigational product. Gemcitabine and cisplatin were reported as co-suspect.</narrativeincludeclinical>
				<sendercomment>Panitumumab is a high-affinity fully human immunoglobulin IgG2 monoclonal antibody that targets the human epidermal growth factor receptor leading to inhibition of EGFr activation.

The event of cholangitis has not been documented as listed or expected in the Amgen Development Core Safety Information for product panitumumab.

Although a temporal association exists, it is not sufficient to establish, or rule out, a causal relationship between panitumumab and the event reported in this case. Additionally, causality is confounded by underlying cholangiocarcinomas and concurrent use of gemcitabine and cisplatin.

This individual case report does not change the safety profile of the product.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
